Mij
Senior Member (Voting Rights)
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
“All patients undergoing transplant are at risk of developing EBV+ PTLD during their life, and in that case, those that do not respond to initial treatment have few treatment options left,” said Dr. Sylvain Choquet, Head of the Clinical Hematology Department at Pitié-Salpêtrière, APHP, France. “There is an urgent unmet need for effective therapies for this rare B-cell lymphoproliferative disease, with data from the pivotal study demonstrating the potential for EbvalloTM to change the treatment of relapsed or refractory EBV+ PTLD and provide a much-needed therapeutic solution to both patients and physicians.”
https://investors.atarabio.com/news...-recommends-approval-of-atara-biotherapeutics
“All patients undergoing transplant are at risk of developing EBV+ PTLD during their life, and in that case, those that do not respond to initial treatment have few treatment options left,” said Dr. Sylvain Choquet, Head of the Clinical Hematology Department at Pitié-Salpêtrière, APHP, France. “There is an urgent unmet need for effective therapies for this rare B-cell lymphoproliferative disease, with data from the pivotal study demonstrating the potential for EbvalloTM to change the treatment of relapsed or refractory EBV+ PTLD and provide a much-needed therapeutic solution to both patients and physicians.”
https://investors.atarabio.com/news...-recommends-approval-of-atara-biotherapeutics